膽固醇檢測市場－全球產業規模、佔有率、趨勢、機會和預測，按產品類型、按檢測類型、按處方模式、按最終用戶、按地區和競爭細分，2020-2030 年

2024年全球膽固醇檢測市場規模達123.6億美元，預計在預測期內將呈現強勁成長，到2030年的複合年成長率為6.92%。膽固醇檢測，也稱為血脂譜或血脂組，是一項重要的醫學檢查，用於評估血液中各種脂質（主要是膽固醇和三酸甘油酯）的水平。此檢測通常測量總膽固醇、低密度脂蛋白（LDL，即「壞」膽固醇）、高密度脂蛋白（HDL，即「好」膽固醇）和三酸甘油酯。這些數值有助於了解一個人的心血管健康狀況，並有助於識別冠狀動脈疾病、心臟病發作和中風等疾病的潛在風險。 LDL水平升高和HDL水平降低會增加動脈斑塊積聚的風險，導致血流受限和嚴重的心臟併發症。對於有心臟病家族史、糖尿病患者或久坐不動且飲食習慣不良的人來說，常規膽固醇檢測尤其重要。及早發現膽固醇水平異常，有助於及時改變生活方式或採取醫療干預措施，例如採用更健康的飲食、增加體能活動或服用降膽固醇藥物。由於膽固醇水平受多種因素影響，包括年齡、遺傳、飲食和整體健康狀況，因此諮詢醫療保健專業人員至關重要。他們可以準確解讀結果，並建議個人化的膽固醇管理策略，以維持長期心血管健康。

關鍵市場促進因素

心血管疾病盛行率上升

主要市場挑戰

技術限制

主要市場趨勢

個人化醫療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球膽固醇檢測市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品類型（測試套件、測試條、其他）
  • 按測試類型（總膽固醇測試、高密度脂蛋白 (HDL) 膽固醇、低密度脂蛋白 (LDL) 膽固醇、三酸甘油酯/VLDL 膽固醇測試）
  • 依處方模式（非處方藥、處方藥）
  • 按最終使用者（醫院和診所、診斷實驗室、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美膽固醇檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲膽固醇檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太膽固醇檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美膽固醇檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲膽固醇檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Abbott Laboratories Inc.
• Beckman Coulter Inc.
• Horiba Ltd.
• Nova Biomedical Corp.
• Roche Holding Ag (F.Hoffmann-La Roche Ltd.)
• Randox Laboratories Ltd.
• Siemens Healthineers Gmbh
• Sekisui Diagnostics LLC
• Sinocare Inc.
• Thermo Fisher Scientific Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

Global Cholesterol Testing Market was valued at USD 12.36 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.92% through 2030. A cholesterol test, also known as a lipid profile or lipid panel, is a vital medical examination used to assess the levels of various lipids-primarily cholesterol and triglycerides-in the bloodstream. This test typically measures total cholesterol, low-density lipoprotein (LDL or "bad" cholesterol), high-density lipoprotein (HDL or "good" cholesterol), and triglycerides. These values offer essential insights into a person's cardiovascular health and help identify potential risks for conditions such as coronary artery disease, heart attacks, and strokes. Elevated LDL levels and low HDL levels can increase the risk of plaque buildup in arteries, leading to restricted blood flow and serious heart complications. Routine cholesterol testing is particularly important for individuals with a family history of heart disease, those with diabetes, or people leading sedentary lifestyles with poor dietary habits. Early detection of abnormal cholesterol levels allows for timely lifestyle changes or medical interventions, such as adopting a healthier diet, increasing physical activity, or using cholesterol-lowering medications. Since cholesterol levels can be influenced by various factors-including age, genetics, diet, and overall health-it is essential to consult with a healthcare professional. They can interpret the results accurately and recommend personalized strategies for managing cholesterol and maintaining long-term cardiovascular wellness.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases, including heart attacks and strokes, often have subtle or asymptomatic early stages. For instance, according to a 2024 article, coronary artery disease (CAD) is a common yet serious heart condition that can lead to heart attacks. A recent study, published in the European Heart Journal, highlights that measuring apolipoprotein B particles and lipoprotein(a) levels may improve risk prediction for CAD. These lipoproteins carry "bad" cholesterol in the blood and play a critical role in plaque buildup in coronary arteries. The Centers for Disease Control and Prevention (CDC) states that CAD is caused by plaque accumulation in the arteries supplying blood to the heart, emphasizing the importance of early screening and preventive care. Cholesterol testing helps identify individuals with high cholesterol levels, who are at an increased risk of developing CVDs. Early detection allows for timely intervention and lifestyle changes that can help prevent or manage the progression of these diseases. Cholesterol testing provides valuable information for risk assessment and stratification. Individuals with elevated cholesterol levels are categorized as high-risk patients for CVDs. This categorization helps healthcare providers tailor treatment and management strategies, potentially preventing future cardiovascular events. For individuals diagnosed with CVDs or at risk of developing them, cholesterol testing is used to monitor the effectiveness of treatments such as medication, dietary changes, and exercise. Regular testing helps healthcare professionals adjust treatment plans as needed to achieve target cholesterol levels. The rising prevalence of cardiovascular diseases underscores the importance of cholesterol testing as a critical tool for prevention, early detection, and management. The increasing demand for cholesterol testing is a natural response to the need to address the growing burden of CVDs and their associated risk factors.

Key Market Challenges

Technological Limitations

While point-of-care testing devices and home testing kits have improved accessibility, their accuracy might not always match that of laboratory-based testing, potentially affecting diagnostic reliability. Point-of-care testing devices and home testing kits might yield results that can vary from one test to another or from laboratory-based measurements. This variability can lead to uncertainty in interpreting results and making clinical decisions. Home testing kits and point-of-care devices rely on individuals performing the test correctly. User errors, such as improper sample collection or incorrect device operation, can significantly impact the accuracy of results. Proper calibration and maintenance of testing devices are crucial for accuracy. Without regular calibration and quality control, point-of-care devices might drift from accurate results over time. Inaccurate results from point-of-care testing or home testing kits can impact clinical decision-making. Incorrect management strategies based on unreliable results might harm patient outcomes.

Key Market Trends

Personalized Medicine

The trend toward personalized medicine will likely extend to cardiovascular health. Cholesterol testing can provide essential data for tailoring interventions and treatment plans based on an individual's unique risk profile. The trend toward personalized medicine has the potential to greatly impact cardiovascular health, and cholesterol testing plays a vital role in this shift. Personalized medicine aims to provide individualized healthcare based on an individual's unique genetic makeup, lifestyle, and other factors. Cholesterol testing offers essential data that can help tailor interventions and treatment plans specifically for an individual's risk profile. Based on an individual's cholesterol levels, genetic factors, medical history, and other health metrics, healthcare providers can create personalized treatment plans. This might involve lifestyle modifications, medication choices, and specific targets for cholesterol levels. Personalized medicine involves continuous monitoring of an individual's health markers. Cholesterol testing serves as a valuable tool for tracking progress and ensuring that the chosen interventions are effective. Regular testing encourages patient adherence to treatment plans. For individuals who require cholesterol-lowering medications, personalized medicine can guide the choice of medications and dosages. Certain medications might be more effective or better tolerated based on an individual's genetic and metabolic factors.

Key Market Players

• Abbott Laboratories Inc.
• Beckman Coulter Inc.
• Horiba Ltd.
• Nova Biomedical
• Roche Holding Ag (F.Hoffmann-La Roche Ltd.)
• Randox Laboratories Ltd.
• Siemens Healthineers Gmbh
• Sekisui Diagnostics LLC
• Sinocare Inc.
• Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Cholesterol Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cholesterol Testing Market, By Product Type:

• Test Kits
• Test Strips
• Other

Cholesterol Testing Market, By Test Type:

• Total Cholesterol Test
• High-Density Lipoprotein (HDL) Cholesterol
• Low-Density Lipoprotein (LDL) Cholesterol
• Triglycerides/VLDL Cholesterol Test

Cholesterol Testing Market, By Prescription Mode:

• Over the Counter
• Prescription Based

Cholesterol Testing Market, By End User:

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Cholesterol Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cholesterol Testing Market.

Available Customizations:

Global Cholesterol Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cholesterol Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type Type (Test Kits, Test Strips, Others)
  • 5.2.2. By Test Type (Total Cholesterol Test, High-Density Lipoprotein (HDL) Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, Triglycerides/VLDL Cholesterol Test)
  • 5.2.3. By Prescription Mode (Over the Counter, Prescription Based)
  • 5.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Cholesterol Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Test Type
  • 6.2.3. By Prescription Mode
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cholesterol Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Prescription Mode
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Cholesterol Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Prescription Mode
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Cholesterol Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Prescription Mode
      • 6.3.3.2.4. By End User

7. Europe Cholesterol Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Test Type
  • 7.2.3. By Prescription Mode
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cholesterol Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Prescription Mode
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Cholesterol Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Prescription Mode
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Cholesterol Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Prescription Mode
      • 7.3.3.2.4. By End User
  • 7.3.4. France Cholesterol Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Prescription Mode
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Cholesterol Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Prescription Mode
      • 7.3.5.2.4. By End User

8. Asia-Pacific Cholesterol Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Test Type
  • 8.2.3. By Prescription Mode
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cholesterol Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Prescription Mode
      • 8.3.1.2.4. By End User
  • 8.3.2. India Cholesterol Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Prescription Mode
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Cholesterol Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Prescription Mode
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Cholesterol Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Prescription Mode
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Cholesterol Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Prescription Mode
      • 8.3.5.2.4. By End User

9. South America Cholesterol Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Test Type
  • 9.2.3. By Prescription Mode
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cholesterol Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Prescription Mode
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Cholesterol Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Prescription Mode
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Cholesterol Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Prescription Mode
      • 9.3.3.2.4. By End User

10. Middle East and Africa Cholesterol Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Test Type
  • 10.2.3. By Prescription Mode
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cholesterol Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Prescription Mode
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Cholesterol Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Prescription Mode
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Cholesterol Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Prescription Mode
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Abbott Laboratories Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Beckman Coulter Inc.
• 14.3. Horiba Ltd.
• 14.4. Nova Biomedical Corp.
• 14.5. Roche Holding Ag (F.Hoffmann-La Roche Ltd.)
• 14.6. Randox Laboratories Ltd.
• 14.7. Siemens Healthineers Gmbh
• 14.8. Sekisui Diagnostics LLC
• 14.9. Sinocare Inc.
• 14.10. Thermo Fisher Scientific Inc.

15. Strategic Recommendations

16. About Us & Disclaimer